KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other Working Capital Changes (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Other Working Capital Changes for 9 consecutive years, with $132000.0 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Other Working Capital Changes rose 111.93% year-over-year to $132000.0, compared with a TTM value of -$721000.0 through Mar 2025, up 85.23%, and an annual FY2025 reading of $7.8 million, up 499.54% over the prior year.
  • Other Working Capital Changes was $132000.0 for Q1 2025 at Biocryst Pharmaceuticals, up from -$2.0 million in the prior quarter.
  • Across five years, Other Working Capital Changes topped out at $6.0 million in Q3 2023 and bottomed at -$8.8 million in Q4 2023.
  • Average Other Working Capital Changes over 3 years is -$339666.7, with a median of -$1.1 million recorded in 2023.
  • The sharpest move saw Other Working Capital Changes crashed 143.42% in 2024, then surged 111.93% in 2025.
  • Year by year, Other Working Capital Changes stood at -$8.8 million in 2023, then surged by 77.64% to -$2.0 million in 2024, then skyrocketed by 106.74% to $132000.0 in 2025.
  • Business Quant data shows Other Working Capital Changes for BCRX at $132000.0 in Q1 2025, -$2.0 million in Q4 2024, and $2.9 million in Q3 2024.